Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells

Zhang,Yunfei; Luo,Wen; Wang,Yucai; Chen,Jun; Liu,Yunyan; Zhang,Yong

doi:10.3892/or.2015.3934

Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells

Authors:
- Yunfei Zhang
- Wen Luo
- Yucai Wang
- Jun Chen
- Yunyan Liu
- Yong Zhang
View Affiliations

Affiliations: Center of Orthopaedic Surgery, Orthopaedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: April 27, 2015 https://doi.org/10.3892/or.2015.3934
Pages: 2695-2702
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor-derived heat shock proteins peptide complex (HSP.PC-Tu) has been regarded as a promising antitumor agent. However, inadequate immunogenicity and low bioavailability limit the clinical uses of this agent. In a previous study, we first produced an improved HSP70.PC‑based vaccine purified from dendritic cell (DC)-tumor fusion cells (HSP70.PC-Fc) which had increased immunogenicity due to enhanced antigenic tumor peptides compared to HSP70.PC-Tu. In order to increase the bioavailability of HSP70.PC-Fc, the peptide complex was encapsulated with nanoliposomes (NL-HSP70.PC-Fc) in this study. After encapsulation, the tumor immunogenicity was observed using various assays. It was demonstrated that the NL-HSP70.PC-Fc has acceptable stability. The in vivo antitumor immune response was increased with regard to T-cell activation, CTL response and tumor therapy efficiency compared to that of HSP70.PC-Fc. In addition, it was shown that DC maturation was improved by NL-HSP70.PC-Fc, which added to the antitumor immunity. The results obtained for NL-HSP70.PC-Fc, which improved immunogenicity and increases the bioavailability of HSP70.PC, may represent superior heat shock proteins (HSPs)-based tumor vaccines. Such vaccines deserve further investigation and may provide a preclinical rationale to translate findings into early phase trials for patients with breast tumors.

View Figures

View References

1	Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A, Gastpar R and Issels RD: Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 18:563–575. 2002. View Article : Google Scholar
2	See AP, Pradilla G, Yang I, Han S, Parsa AT and Lim M: Heat shock protein-peptide complex in the treatment of glioblastoma. Expert Rev Vaccines. 10:721–731. 2011. View Article : Google Scholar : PubMed/NCBI
3	Murshid A, Gong J, Stevenson MA and Calderwood SK: Heat shock proteins and cancer vaccines Developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines. 10:1553–1568. 2011. View Article : Google Scholar : PubMed/NCBI
4	Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, et al: Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 19:205–214. 2013. View Article : Google Scholar
5	Shinagawa N, Yamazaki K, Tamura Y, Imai A, Kikuchi E, Yokouchi H, Hommura F, Oizumi S and Nishimura M: Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8⁺ cytotoxic T lymphocytes and natural killer cells. Cancer Immunol Immunother. 57:165–174. 2008. View Article : Google Scholar
6	Tamura Y, Peng P, Liu K, Daou M and Srivastava PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 278:117–120. 1997. View Article : Google Scholar : PubMed/NCBI
7	Sato K, Tonmoto Y, Tamura Y, Shindo M, Shinzaki H, Hirai K and Kohgo Y: Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood. 98:1852–1857. 2001. View Article : Google Scholar : PubMed/NCBI
8	Snvastava PK: Immunotherapy of human cancer: lessons from mice. Nat Immunol. 1:363–366. 2000. View Article : Google Scholar
9	Kojima T, Yamazaki K, Tamura Y, Ogura S, Tani K, Konishi J, Shinagawa N, Kinoshita I, Hizawa N, Yamaguchi E, et al: Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice. Hum Gene Ther. 14:715–728. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kovalchin JT, Murthy AS, Horattas MC, Guyton DP and Chandawarkar RY: Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun. 1:72001.
11	Teston A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiam G, Tosti G, Kirkwood JM, Hoos A, et al: C-100-21 Study Group phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma the C-100-21 Study Group. J Clin Oncol. 26:955–962. 2008. View Article : Google Scholar
12	Wood C, Snvastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, et al: C-100-12 RCC Study Group an adjuvant autologous therapeutic vaccine (HSPPC-96, vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma A multicentre, open-label, randomised phase III trial. Lancet. 372:145–154. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gong J, Zhang Y, Durfee J, Weng D, Liu C, Koido S, Song B, Apostolopoulos V and Calderwood SK: A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol. 184:488–496. 2010. View Article : Google Scholar :
14	Mensko-Liversidge E, Liversidge GG and Cooper ER: Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 18:113–120. 2003. View Article : Google Scholar
15	Moghimi SM, Hunter AC and Murray JC: Long-circulating and target-specific nanoparticles theory to practice. Pharmacol Rev. 53:283–318. 2001.PubMed/NCBI
16	Conniot J, Silva JM, Fernandes JG, Silva LC, Caspar R, Brocchim S, Flonndo HF and Barata TS: Cancer immunotherapy nanodehvery approaches for immune cell targeting and tracking. Front Chem. 2:1052014. View Article : Google Scholar
17	Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G and Prassl R: Liposomal vasoactive intestinal peptide for lung application protection from proteolytic degradation. Eur J Pharm Biopharm. 70:153–164. 2008. View Article : Google Scholar : PubMed/NCBI
18	Pulaski BA and Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B71 cell-based tumor vaccines. Cancer Res. 58:1486–1493. 1998.PubMed/NCBI
19	Inaba K, Inaba M, Romam N, Aya H, Deguchi M, Ikehara S, Muramatsu S and Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 176:1693–1702. 1992. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Luo W, Wang Y, Liu Y and Zheng L: Purified dendritic cell-tumor fusion hybrids supplemented with non-adherent dendritic cells fraction are superior activators of antitumor immunity. PLoS One. 9:e867722014. View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, Sui Y, Zhang X, Ma B and Fan Q: Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat. 105:277–286. 2007. View Article : Google Scholar
22	Ryland LK, Doshi UA, Shanmugavelandy SS, Fox TE, Aliaga C, Broeg K, Baab KT, Young M, Khan O, Haakenson JK, et al: C6-ceramide nanohposomes target the Warburg effect in chronic lymphocytic leukemia. PLoS One. 8:e846482013. View Article : Google Scholar
23	Chang YJ, Chang CH, Chang TJ, Yu CY, Chen LC, Jan ML, Luo TY, Lee TW and Ting G: Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res. 27(4B): 2217–2225. 2007.PubMed/NCBI
24	Dadgar N, Alavi SE, Esfahani MK and Akbarzadeh A: Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line. Indian J Clin Biochem. 28:410–412. 2013. View Article : Google Scholar :
25	Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem. 234:466–468. 1959.PubMed/NCBI
26	Gao D, Tang S and Tong Q: Oleanolic acid liposomes with polyethylene glycol modification Promising antitumor drug delivery. Int J Nanomed. 7:3517–3526. 2012. View Article : Google Scholar
27	Rashid OM, Nagahashi M, Ramachandran S, Dumur C, Schaum J, Yamada A, Terracina KP, Milstien S, Spiegel S and Takabe K: An improved syngeneic orthotopic murine model of human breast cancer progression. Breast Cancer Res Treat. 147:501–512. 2014. View Article : Google Scholar : PubMed/NCBI
28	Noessner E, Gastpar R, Milani V, Brandi A, Hutzier PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, et al: Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol. 169:5424–5432. 2002. View Article : Google Scholar : PubMed/NCBI
29	Castelli C, Ciupitu AM, Rim F, Rivoltim L, Mazzocchi A, Kiesshng R and Parmiam G: Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61:222–227. 2001.PubMed/NCBI
30	Zhang Y and Zheng L: Tumor immunotherapy based on tumor-derived heat shock proteins (Review). Oncol Lett. 6:1543–1549. 2013.PubMed/NCBI
31	Tosti G, Cocorocchio E, Pennacchioli E, Ferrucci PF, Teston A and Martinoli C: Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and lmmunomodulating agents. Expert Opin Biol Ther. 14:955–967. 2014. View Article : Google Scholar : PubMed/NCBI
32	Hamman JH and Enslin GM: Kotzé AF Oral delivery of peptide drugs barriers and developments. BioDrugs. 19:165–177. 2005. View Article : Google Scholar
33	Vyas SP and Gupta PN: Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines. 6:401–418. 2007. View Article : Google Scholar : PubMed/NCBI
34	Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, et al: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med. 10:1562012. View Article : Google Scholar : PubMed/NCBI
35	Ge W, Hu PZ, Huang Y, Wang XM, Zhang XM, Sun YJ, Li ZS, Si SY and Sui YF: The antitumor immune responses induced by nanoemulsion-encapsulated maGe1-HSP70/Sea complex protein vaccine following different administration routes. Oncol Rep. 22:915–920. 2009.PubMed/NCBI
36	Ge W, Li Y, Li ZS, Zhang SH, Sun YJ, Hu PZ, Wang XM, Huang Y, Si SY, Zhang XM, et al: The antitumor immune responses induced by nanoemulsion-encapsulated maGe1-HSP70/Sea complex protein vaccine following peroral administration route. Cancer Immunol Immunother. 58:201–208. 2009. View Article : Google Scholar
37	Gabizon A and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA. 85:6949–6953. 1988. View Article : Google Scholar : PubMed/NCBI
38	Nakase I, Lai H, Singh NP and Sasaki T: Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm. 354:28–33. 2008. View Article : Google Scholar
39	Veronese FM: Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22:405–417. 2001. View Article : Google Scholar : PubMed/NCBI
40	Ryan SM, Mantovani G, Wang X, Haddleton DM and Brayden DJ: Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin Drug Deliv. 5:371–383. 2008. View Article : Google Scholar : PubMed/NCBI
41	Matteucci ML and Thrall DE: The role of liposomes in drug delivery and diagnostic imaging: a review. Vet Radiol Ultrasound. 41:100–107. 2000. View Article : Google Scholar : PubMed/NCBI
42	Pedroso de Lima MC, Neves S, Filipe A, Düzgüneş N and Simões S: Cationic liposomes for gene delivery: From biophysics to biological applications. Curr Med Chem. 10:1221–1231. 2003. View Article : Google Scholar : PubMed/NCBI
43	Bakker-Woudenberg IA, Storm G and Woodle MC: Liposomes in the treatment of infections. J Drug Target. 2:363–371. 1994. View Article : Google Scholar : PubMed/NCBI
44	Im SA, Kim KH, Ji HG, Yu HG, Park SK and Lee CK: Nanoliposomes of L-lysine-conjugated poly (aspartic acid) Increase the Generation and Function of Bone Marrow-derived Dendritic Cells. Immune Netw. 11:281–287. 2011. View Article : Google Scholar : PubMed/NCBI